As in years past, trial results offered up a mixed bag of goods and duds at the Clinical Trials on Alzheimer’s Disease Conference, held October 24–27 in Barcelona, Spain. In the first Phase 3 AD trial ever conducted in China, a seaweed oligosaccharide was claimed to have halted or even reversed the slide into dementia of people with mild to moderate Alzheimer’s. In a more familiar story, another offbeat approach—a plasma exchange therapy—was reported to slow decline in people with moderate, but not mild, AD. Not so for the fyn kinase inhibitor saracatinib, which hit the end of the road. New Aβ vaccines advanced, and the first clinical trial of an antiviral drug potentially offers a new angle on AD. Finally, the neurosteroid allopregnanolone inched ahead, though estrogen receptor-modulating PhytoSERMs did not.
To read the rest of this blog and the second part visit the Alz Forum Website: https://www.alzforum.org/news/conference-coverage/fits-and-starts-trial-results-ctad-conference